These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 15250062)
41. Paricalcitol for treatment of secondary hyperparathyroidism in CKD patients. Drüeke TB; Landais P Am J Kidney Dis; 2006 Jun; 47(6):1083; author reply 1083-4. PubMed ID: 16731305 [No Abstract] [Full Text] [Related]
42. Dynamics of cinacalcet use and biochemical control in hemodialysis patients: a retrospective New-user cohort design. Reams BD; Dluzniewski PJ; Do TP; Yue SV; Bradbury BD; Kshirsagar AV; Brookhart MA BMC Nephrol; 2015 Oct; 16():175. PubMed ID: 26510587 [TBL] [Abstract][Full Text] [Related]
43. Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience. Lucchi L; Carboni C; Stipo L; Malaguti V; Ferrari F; Graziani R; Arletti S; Graziosi C Artif Organs; 2011 Dec; 35(12):1186-93. PubMed ID: 21848793 [TBL] [Abstract][Full Text] [Related]
44. The role of cinacalcet in treating secondary hyperparathyroidism. Brommage D; Gallgano C Nephrol Nurs J; 2005; 32(2):229-31. PubMed ID: 15889812 [TBL] [Abstract][Full Text] [Related]
45. Safety and efficiency of treatment with cinacalcet of haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism. Kuczera P; Adamczak M; Więcek A Endokrynol Pol; 2013; 64(3):176-81. PubMed ID: 23873419 [TBL] [Abstract][Full Text] [Related]
46. Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism. Ichii M; Ishimura E; Okuno S; Chou H; Kato Y; Tsuboniwa N; Nagasue K; Maekawa K; Yamakawa T; Inaba M; Nishizawa Y Nephron Clin Pract; 2010; 115(3):c195-202. PubMed ID: 20413997 [TBL] [Abstract][Full Text] [Related]
47. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294 [TBL] [Abstract][Full Text] [Related]
48. 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Jean G; Chazot C; Charra B Clin Nephrol; 2007 Jul; 68(1):63-4. PubMed ID: 17703841 [No Abstract] [Full Text] [Related]
49. Management of serum calcium reductions among patients on hemodialysis following cinacalcet initiation. Brunelli SM; Dluzniewski PJ; Cooper K; Do TP; Sibbel S; Bradbury BD Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1058-67. PubMed ID: 26238994 [TBL] [Abstract][Full Text] [Related]
50. Asymptomatic polyostotic Paget's disease associated with secondary hyperparathyroidism in a peritoneal dialysis patient. De Sousa-Amorim E; Del Peso-Gilsanz G; Bajo-Rubio MA; Selgas-Gutiérrez R Nefrologia; 2012 Jul; 32(4):542-4. PubMed ID: 22806296 [No Abstract] [Full Text] [Related]
52. Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients. Hirai T; Nakashima A; Takasugi N; Yorioka N Ther Apher Dial; 2010 Dec; 14(6):577-82. PubMed ID: 21118366 [TBL] [Abstract][Full Text] [Related]
53. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690 [TBL] [Abstract][Full Text] [Related]
54. Minimal impact of calcimimetics on the management of hyperparathyroidism in chronic dialysis. Brunaud L; Ngueyon Sime W; Filipozzi P; Nomine-Criqui C; Aronova A; Zarnegar R; Kessler M; Frimat L; Ayav C Surgery; 2016 Jan; 159(1):183-91. PubMed ID: 26476826 [TBL] [Abstract][Full Text] [Related]
55. Impact of cinacalcet hydrochloride on the achievement of the Japanese Society for Dialysis Therapy (JSDT) guideline targets: a post-hoc analysis of the KRN1493 study. Komaba H; Fukagawa M; Ther Apher Dial; 2008 Oct; 12 Suppl 1():S44-9. PubMed ID: 19032527 [TBL] [Abstract][Full Text] [Related]
56. [Pharmacological and clinical profiles of calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients on dialysis (cinacalcet hydrochloride, REGPARA)]. Nagano N; Kawata T; Wada M Nihon Yakurigaku Zasshi; 2008 Nov; 132(5):301-8. PubMed ID: 19008642 [No Abstract] [Full Text] [Related]
57. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism. Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690 [TBL] [Abstract][Full Text] [Related]
58. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Serra AL; Savoca R; Huber AR; Hepp U; Delsignore A; Hersberger M; Wüthrich RP Nephrol Dial Transplant; 2007 Feb; 22(2):577-83. PubMed ID: 17005527 [TBL] [Abstract][Full Text] [Related]
60. A novel dose regimen of cinacalcet in the treatment of severe hyperparathyroidism in hemodialysis patients. Al-Hilali N; Hussain N; Kawy YA; Al-Azmi M Saudi J Kidney Dis Transpl; 2011 May; 22(3):448-55. PubMed ID: 21566299 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]